{"id":"NCT02699099","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.","officialTitle":"Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-10","primaryCompletion":"2018-03-14","completion":"2020-10-07","firstPosted":"2016-03-04","resultsPosted":"2019-08-29","lastUpdate":"2021-09-29"},"enrollment":699,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Malaria","Malaria Vaccines"],"interventions":[{"type":"DIETARY_SUPPLEMENT","name":"Vitamin A","otherNames":[]},{"type":"BIOLOGICAL","name":"Candidate Plasmodium falciparum malaria vaccine","otherNames":["GSK Biologicals' candidate Plasmodium falciparum malaria vaccine adjuvanted with GSK Biologicals' proprietary Adjuvant System AS01E (RTS,S/AS01E)"]},{"type":"BIOLOGICAL","name":"MR-Vac","otherNames":["Live attenuated measles virus and rubella virus vaccine (MR-Vac)"]},{"type":"BIOLOGICAL","name":"Stamaril","otherNames":["Yellow Fever (YF) Vaccine"]}],"arms":[{"label":"Coad group","type":"EXPERIMENTAL"},{"label":"RTS,S group","type":"EXPERIMENTAL"},{"label":"Control group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of the SB257049 candidate malaria vaccine when co-administered with Vitamin A, measles, rubella and yellow fever vaccines to children aged 6 months at the first vaccination.","primaryOutcome":{"measure":"Anti-Circumsporozoite (Anti-CS) Antibody Concentrations, One Month Post Dose 3 of SB257049 (Primary Analysis)","timeFrame":"At one month post Dose 3 of SB257049 (Month 4)","effectByArm":[{"arm":"Coad Group","deltaMin":452.87,"sd":null},{"arm":"RTS,S Group","deltaMin":422.49,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":19},"locations":{"siteCount":2,"countries":["Ghana"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":61,"n":231},"commonTop":["Upper respiratory tract infection","Gastroenteritis","Pyrexia","Respiratory tract infection","Malaria"]}}